Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B

Principal Investigator

Dr Saket Badle

Contact us

Email: Ashley.Yburan@ouh.nhs.uk

IRAS number

1010779